, Tracking Stock Market Picks
Enter Symbol:
Celldex Therapeutics, Inc. (CLDX) [hlAlert]

up 151.83 %

CELLDEX THERAPEUTICS (CLDX) rated Buy by Merriman Curhan Ford

Posted on: Friday,  Oct 24, 2008  8:25 AM ET by Merriman Curhan Ford

Merriman Curhan Ford rated Buy Celldex Therapeutics, Inc. (NASDAQ: CLDX) on 10/24/2008, when the stock price was $6.00.
Since then, Celldex Therapeutics, Inc. has gained 151.83% as of 01/25/2016's recent price of $15.11.
If you would have followed this Merriman Curhan Ford's recommendation on CLDX, you would have gained 151.83% of your investment in 2649 days.

Celldex Therapeutics, Inc. (Celldex) is a biopharmaceutical company, which applies its Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. The Company?s immunotherapy platform includes a portfolio of monoclonal antibodies, antibody-targeted vaccines, antibody-drug conjugates and immunomodulators to create disease-specific drug candidates. Its collaborations include the commercialization of an oral human rotavirus vaccine and the development of oncology and infectious disease vaccines. On October 1, 2009, Celldex acquired CuraGen Corporation.

We occupy a unique niche among our investment banking peers: we offer our clients both traditional sell-side equity research and primary market research, and we focus on high-potential sectors such as CleanTech, Consumer/Internet/Media, Health Care and Tech/Telecom. Our institutional and corporate clients get the best of both worlds: expertise from our analysts and access to experts through our Panel Intelligence platform.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/24/2008 8:25 AM Buy
as of 8/27/2015
1 Week down  -29.98 %
1 Month down  -42.46 %
3 Months down  -41.32 %
1 YTD down  -37.58 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy